Role of Angiogenesis in the Progression and Treatment of Prostate Cancer

REFERENCES

• Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 1992; 267: 10931–10934
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease. Nat. Med. 1995; 1: 27–31
   PubMed Web of Science ®Google Scholar
• Pepper M. S. Manipulating Angiogenesis. From Basic Science to the Bedside. Arterioscler Thromb. Vasc. Biol. 1997; 17: 605–619
   PubMed Web of Science ®Google Scholar
• Hanahan D., Folkman J. Patterns and Emerging Mechanisms of the Angiogenic Switch During Tumorigenesis. Cell 1996; 86: 353–364
   PubMed Web of Science ®Google Scholar
• Risau W. Mechanisms of Angiogenesis. Nature 1997; 386: 671–674
   PubMed Web of Science ®Google Scholar
• Hanahan D. Signaling Vascular Morphogenesis and Maintenance [Comment]. Science 1997; 277: 48–50
   PubMed Web of Science ®Google Scholar
• Folkman J., Ingber D. Inhibition of Angiogenesis. Semin. Cancer. Biol. 1992; 3: 89–96
   PubMedGoogle Scholar
• Saphir A. Angiogenesis: The Unifying Concept in Cancer? [News]. J. Natl. Cancer. Inst. 1997; 89: 1658–1659
   PubMed Web of Science ®Google Scholar
• Voest E. E. Inhibitors of Angiogenesis in a Clinical Perspective. Anticancer Drugs 1996; 7: 723–727
   PubMed Web of Science ®Google Scholar
• Sato T. N. A New Approach to Fighting Cancer?. Proc. Natl. Acad. Sci. USA 1998; 95: 5843–5844
   PubMed Web of Science ®Google Scholar
• Skobe M., Rockwell P., Goldstein N., Vosseler S., Fusenig N. E. Halting Angiogenesis Suppresses Carcinoma Cell Invasion. Nat. Med. 1997; 3: 1222–1227
   PubMed Web of Science ®Google Scholar
• Holash J., Maisonpierre D., Compton D., Boland P., Alexander C. R., Zagzag D., Yancopoulos G. D., Wiegland S. J. Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF. Science 1999; 284: 1994–1998
   PubMed Web of Science ®Google Scholar
• Bergers G., Javaherian K., Lo K. M., Folkman J., Hanahan D. Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice. Science 1999; 284: 808–812
   PubMed Web of Science ®Google Scholar
• Benjamin L. E., Keshet E. Conditional Switching of Vascular Endothelial Growth Factor (VEGF) Expression in Tumors: Induction of Endothelial Cell Shedding and Regression of Hemangioblastoma-like Vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. USA 1997; 94: 8761–8766
   PubMed Web of Science ®Google Scholar
• Benjamin L. E., Golijanin D., Itin A., Pode D., Keshet E. Selective Ablation of Immature Blood Vessels in Established Human Tumors Follows Vascular Endothelial Growth Factor Withdrawal. J. Clin. Invest. 1999; 103: 159–165
   PubMed Web of Science ®Google Scholar
• Davis S., Aldrich T. H., Jones P. F., Acheson A., Compton D. L., Jain V., Ryan T. E., Bruno J., Radziejewski C., Maisonpierre P. C., Yancopoulos G. D. Isolation of Angiopoietin-1, A Ligand for the TIE2 Receptor, by Secretion-trap Expression Cloning. Cell 1996; 87: 1161–1169
   PubMed Web of Science ®Google Scholar
• Koblizek T. I., Weiss C., Yancopoulos G. D., Deutsch U., Risau W. Angiopoietin-1 Induces Sprouting Angiogenesis in Vitro. Curr. Biol. 1998; 8: 529–532
   PubMed Web of Science ®Google Scholar
• Leung D. W., Cachianes G., Kuang W. J., Goeddel D. V., Ferrara N. Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen. Science 1989; 246: 1306–1309
   PubMed Web of Science ®Google Scholar
• Flamme I., Breier G., Risau W. Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor 2 (flk-1) are Expressed During Vasculogenesis and Vascular Differentiation in the Quail Embryo. Dev. Biol. 1995; 169: 699–712
   PubMed Web of Science ®Google Scholar
• Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K. S., Powell-Braxton L., Hillan K. J., Moore M. W. Heterozygous Embryonic Lethality Induced by Targeted Inactivation of the VEGF Gene. Nature 1996; 380: 439–442
   PubMed Web of Science ®Google Scholar
• Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A. Abnormal Blood Vessel Development and Lethality in Embryos Lacking a Single VEGF Allele. Nature 1996; 380: 435–439
   PubMed Web of Science ®Google Scholar
• Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular Endothelial Growth Factor (VEGF) and its Receptors. Faseb. J. 1999; 13: 9–22
   PubMed Web of Science ®Google Scholar
• Neufeld G., Cohen T., Gitay-Goren H., Poltorak Z., Tessler S., Sharon R., Gengrinovitch S., Levi B. Z. Similarities and Differences Between the Vascular Endothelial Growth Factor (VEGF) Splice Variants. Cancer Metastasis Rev. 1996; 15: 153–158
   PubMed Web of Science ®Google Scholar
• Olofsson B., Pajusola K., Kaipainen A., von Euler G., Joukov V., Saksela O., Orpana A., Pettersson R. F., Alitalo K., Eriksson U. Vascular Endothelial Growth Factor B, A Novel Growth Factor for Endothelial Cells. Proc. Natl. Acad. Sci. USA 1996; 93: 2576–2581
   PubMed Web of Science ®Google Scholar
• Olofsson B., Pajusola K., von Euler G., Chilov D., Alitalo K., Eriksson U. Genomic Organization of the Mouse and Human Genes for Vascular Endothelial Growth Factor B (VEGF-B) and Characterization of a Second Splice Isoform. J. Biol. Chem. 1996; 271: 19310–19317
   PubMed Web of Science ®Google Scholar
• Chilov D., Kukk E., Taira S., Jeltsch M., Kaukonen J., Palotie A., Joukov V., Alitalo K. Genomic Organization of Human and Mouse Genes for Vascular Endothelial Growth Factor C. J. Biol. Chem. 1997; 272: 25176–25183
   Google Scholar
• Paavonen K., Horelli-Kuitunen N., Chilov D., Kukk E., Pennanen S., Kallioniemi O. P., Pajusola K., Olofsson B., Eriksson U., Joukov V., Palotie A., Alitalo K. Novel Human Vascular Endothelial Growth Factor Genes VEGF-B and VEGF-C Localize to Chromosomes 11q13 and 4q34, Respectively. Circulation 1996; 93: 1079–1082
   PubMed Web of Science ®Google Scholar
• Witzenbichler B., Asahara T., Murohara T., Silver M., Spyridopoulos I., Magner M., Principe N., Kearney M., Hu J. S., Isner J. M. Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia. Am. J. Pathol. 1998; 153: 381–394
   PubMed Web of Science ®Google Scholar
• Lagercrantz J., Farnebo F., Larsson C., Tvrdik T., Weber G., Piehl F. A Comparative Study of the Expression Patterns for Vegf, Vegf-b/Vrf and Vegf-c in the Developing and Adult Mouse. Biochim. Biophys. Acta. 1998; 1398: 157–163
   PubMed Web of Science ®Google Scholar
• Oh S. J., Jeltsch M. M., Birkenhager R., McCarthy J. E., Weich H. A., Christ B., Alitalo K., Wilting J. VEGF and VEGF-C: Specific Induction of Angiogenesis and Lymphangiogenesis in the Differentiated Avian Chorioallantoic Membrane. Dev. Biol. 1997; 188: 96–109
   PubMed Web of Science ®Google Scholar
• Salven P., Lymboussaki A., Heikkila P., Jaaskela-Saari H., Enholm B., Aase K., von Euler G., Eriksson U., Alitalo K., Joensuu H. Vascular Endothelial Growth Factors VEGF-B and VEGF-C are Expressed in Human Tumors. Am. J. Pathol. 1998; 153: 103–108
   PubMed Web of Science ®Google Scholar
• Joukov V., Kaipainen A., Jeltsch M., Pajusola K., Olofsson B., Kumar V., Eriksson U., Alitalo K. Vascular Endothelial Growth Factors VEGF-B and VEGF-C. J. Cell. Physiol. 1997; 173: 211–215
   PubMed Web of Science ®Google Scholar
• Enholm B., Paavonen K., Ristimaki A., Kumar V., Gunji Y., Klefstrom J., Kivinen L., Laiho M., Olofsson B., Joukov V., Eriksson U., Alitalo K. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA Regulation by Serum, Growth Factors, Oncoproteins and Hypoxia. Oncogene. 1997; 14: 2475–2483
   PubMed Web of Science ®Google Scholar
• Achen M. G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A. F., Alitalo K., Stacker S. A. Vascular Endothelial Growth Factor D (VEGF-D) is a Ligand for the Tyrosine Kinases VEGF Receptor 2 (Flk1) and VEGF Receptor 3 (Flt4). Proc. Natl. Acad. Sci. USA 1998; 95: 548–553
   PubMed Web of Science ®Google Scholar
• Ogawa S., Oku A., Sawano A., Yamaguchi S., Yazaki Y., Shibuya M. A Novel Type of Vascular Endothelial Growth Factor, VEGF-E (NZ-7, VEGF), Prefrentially Utilizes KDR/Flk-1 Receptor and Carries a Potent Mitotic Activity Without Heparin-binding Domain. The Journal of Biological Chemistry 1998; 273: 31273–31282
   PubMed Web of Science ®Google Scholar
• Klagsbrun M., D'Amore P. A. Vascular Endothelial Growth Factor and its Receptors. Cytokine. Growth. Factor. Rev. 1996; 7: 259–270
   PubMedGoogle Scholar
• Ortega N., Jonca F., Vincent S., Favard C., Ruchoux M. M., Plouet J. Systemic Activation of the Vascular Endothelial Growth Factor Receptor KDR/flk-1 Selectively Triggers Endothelial Cells with an Angiogenic Phenotype. Am. J. Pathol. 1997; 151: 1215–1224
   PubMed Web of Science ®Google Scholar
• Shalaby F., Rossant J., Yamaguchi T. P., Gertsenstein M., Wu X. F., Breitman M. L., Schuh A. C. Failure of Blood-island Formation and Vasculogenesis in Flk-1-deficient Mice. Nature 1995; 376: 62–66
   PubMed Web of Science ®Google Scholar
• Millauer B., Shawver L. K., Plate K. H., Risau W., Ullrich A. Glioblastoma Growth Inhibited in Vivo by a Dominant-Negative Flk-1 Mutant. Nature 1994; 367: 576–579
   PubMed Web of Science ®Google Scholar
• Weidner N., Carroll P. R., Flax J., Blumenfeld W., Folkman J. Tumor Angiogenesis Correlates With Metastasis in Invasive Prostate Carcinoma. Am. J. Pathol. 1993; 143: 401–409
   PubMed Web of Science ®Google Scholar
• Wakui S., Furusato M., Itoh T., Sasaki H., Akiyama A., Kinoshita I., Asano K., Tokuda T., Aizawa S., Ushigome S. Tumour Angiogenesis in Prostatic Carcinoma with and without Bone Marrow Metastasis: A Morphometric Study. J. Pathol. 1992; 168: 257–262
   PubMed Web of Science ®Google Scholar
• Furusato M., Wakui S., Sasaki H., Ito K., Ushigome S. Tumour Angiogenesis in Latent Prostatic Carcinoma. Br. J. Cancer 1994; 70: 1244–1246
   PubMed Web of Science ®Google Scholar
• Borre M., Offersen B. V., Nerstrom B., Overgaard J. Microvessel Density Predicts Survival in Prostate Cancer Patients Subjected to Watchful Waiting. Br. J. Cancer 1998; 78: 940–944
   PubMed Web of Science ®Google Scholar
• Campbell C. L., Savarese D. M., Quesenberry P. J., Savarese T. M. Expression of Multiple Angiogenic Cytokines in Cultured Normal Human Prostate Epithelial Cells: Predominance of Vascular Endothelial Growth Factor. Int. J. Cancer 1999; 80: 868–874
   PubMed Web of Science ®Google Scholar
• Jackson M. W., Bentel J. M., Tilley W. D. Vascular Endothelial Growth Factor (VEGF) Expression in Prostate Cancer and Benign Prostatic Hyperplasia [See Comments]. J. Urol. 1997; 157: 2323–2328
   PubMed Web of Science ®Google Scholar
• Ferrer F. A., Miller L. J., Andrawis R. I., Kurtzman S. H., Albertsen P. C., Laudone V. P., Kreutzer D. L. Angiogenesis and Prostate Cancer: In Vivo and in Vitro Expression of Angiogenesis Factors by Prostate Cancer Cells. Urology 1998; 51: 161–167
   PubMed Web of Science ®Google Scholar
• Ferrer F. A., Miller L. J., Andrawis R. I., Kurtzman S. H., Albertsen P. C., Laudone V. P., Kreutzer D. L. Vascular Endothelial Growth Factor (VEGF) Expression in Human Prostate Cancer: in Ditu and in Vitro Expression of VEGF by Human Prostate Cancer Cells. J. Urol. 1997; 157: 2329–2333
   PubMed Web of Science ®Google Scholar
• Salven P., Manpaa H., Orpana A., Alitalo K., Joensuu H. Serum Vascular Endothelial Growth Factor is Often Elevated in Disseminated Cancer. Clin. Cancer Res. 1997; 3: 647–651
   PubMed Web of Science ®Google Scholar
• Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K. A Novel Vascular Endothelial Growth Factor, VEGF-C, is a Ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) Receptor Tyrosine Kinases [Published Erratum Appears in EMBO. J. 1996, Apr. 1, 15(7), 1751]. Embo. J. 1996; 15: 290–298
   PubMed Web of Science ®Google Scholar
• Tsurusaki T., Kanda S., Sakai H., Kanetake H., Saito Y., Alitalo K., Koji T. Vascular Endothelial Growth Factor-C Expression in Human Prostatic Carcinoma and its Relationship to Lymph Node Metastasis. Br. J. Cancer 1999; 80: 309–313
   PubMed Web of Science ®Google Scholar
• Haggstrom S., Wikstrom P., Bergh A., Damber J. E. Expression of Vascular Endothelial Growth Factor and its Receptors in the Rat Ventral Prostate and Dunning R3327 PAP Adenocarcinoma Before and After Castration. Prostate 1998; 36: 71–79
   PubMed Web of Science ®Google Scholar
• Ferrer F. A., Miller L. J., Lindquist R., Kowalczyk P., Laudone V. P., Albertsen P. C., Kreutzer D. L. Expression of Vascular Endothelial Growth Factor Receptors in Human Prostate Cancer [In Process Citation]. Urology 1999; 54: 567–572
   PubMed Web of Science ®Google Scholar
• Joseph I. B., Nelson J. B., Denmeade S. R., Isaacs J. T. Androgens Regulate Vascular Endothelial Growth Factor Content in Normal and Malignant Prostatic Tissue. Clin. Cancer Res. 1997; 3: 2507–2511
   PubMed Web of Science ®Google Scholar
• Jain R. K., Safabakhsh N., Sckell A., Chen Y., Jiang P., Benjamin L., Yuan F., Keshet E. Endothelial Cell Death, Angiogenesis, and Microvascular Function After Castration in an Androgen-dependent Tumor: Role of Vascular Endothelial Growth Factor. Proc. Natl. Acad. Sci. USA 1998; 95: 10820–10825
   PubMed Web of Science ®Google Scholar
• Sordello S., Bertrand N., Plouet J. Vascular Endothelial Growth Factor is Up-regulated in Vitro and in Vivo by Androgens. Biochem. Biophys. Res. Commun. 1998; 251: 287–290
   PubMed Web of Science ®Google Scholar
• Borgstrom P., Bourdon M. A., Hillan K. J., Sriramarao P., Ferrara N. Neutralizing Anti-vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors in Vivo. Prostate 1998; 35: 1–10
   PubMed Web of Science ®Google Scholar
• Melnyk O., Zimmerman M., Kim K. J., Shuman M. Neutralizing Anti-vascular Endothelial Growth Factor Antibody Inhibits Further Growth of Established Prostate Cancer and Metastases in A Pre-Clinical Model. J. Urol. 1999; 161: 960–963
   PubMed Web of Science ®Google Scholar
• Fong T. A., Shawver L. K., Sun L., Tang C., App H., Powell T. J., Kim Y. H., Schreck R., Wang X., Risau W., Ulrich A., Hirth K. P., McMahon G. SU5416 is a Potent and Selective Inhibitor of the Vascular Endothelil Growth Factor Receptor (Flk-1/KDR) that Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types. Cancer Research 1999; 59: 99–106
   PubMed Web of Science ®Google Scholar
• Zhu Z., Rockwell P., Lu D., Kotanides H., Pytowski B., Hicklin D. J., Bohlen P., Witte L. Inhibition of Vascular Endothelial Growth Factor-Induced Receptor Activation with Anti-kinase Insert Domain-containing Receptor Single-chain Antibodies from a Phage Display Library. Cancer Res. 1998; 58: 3209–3214
   PubMed Web of Science ®Google Scholar
• Witte L., Hicklin D. J., Zhu Z., Pytowski B., Kotanides H., Rockwell P., Bohlen P. Monoclonal Antibodies Targeting the VEGF Receptor-2 (Flk1/KDR) as an Anti-Angiogenic Therapeutic Strategy. Cancer Metastasis. Rev. 1998; 17: 155–161
   PubMed Web of Science ®Google Scholar
• Hanemaaijer R., Koolwijk P., le Clercq L., de Vree W. J., van Hinsbergh V. W. Regulation of Matrix Metalloproteinase Expression in Human Vein and Microvascular Endothelial Cells. Effects of Tumour Necrosis Factor Alpha, Interleukin 1 and Phorbol Ester. Biochem. J. 1993; 296: 803–809
   PubMed Web of Science ®Google Scholar
• Himelstein B. P., Canete-Soler R., Bernhard E. J., Dilks D. W., Muschel R. J. Metalloproteinases in Tumor Progression: the Contribution of MMP-9. Invasion Metastasis 1994; 14: 246–258
   PubMedGoogle Scholar
• Lokeshwar B. L., Selzer M. G., Block N. L., Gunja-Smith Z. Secretion of Matrix Metalloproteinases and their Inhibitors (Tissue Inhibitor of Metalloproteinases) by Human Prostate in Explant Cultures: Reduced Tissue Inhibitor of Metalloproteinase Secretion by Malignant Tissues. Cancer Res. 1993; 53: 4493–4498
   PubMed Web of Science ®Google Scholar
• Hamdy F. C., Fadlon E. J., Cottam D., Lawry J., Thurrell W., Silcocks P. B., Anderson J. B., Williams J. L., Rees R. C. Matrix Metalloproteinase 9 Expression in Primary Human Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia. Br. J. Cancer 1994; 69: 177–182
   PubMed Web of Science ®Google Scholar
• Montironi R., Fabris G., Lucarini G., Biagini G. Location of 72-kd Metalloproteinase (Type IV Collagenase) in Untreated Prostatic Adenocarcinoma. Pathol. Res. Pract. 1995; 191: 1140–1146
   PubMed Web of Science ®Google Scholar
• Brooks P. C., Silletti S., von Schalscha T. L., Friedlander M., Cheresh D. A. Disruption of Angiogenesis by PEX, A Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity. Cell 1998; 92: 391–400
   PubMed Web of Science ®Google Scholar
• Haas T. L., Madri J. A. Extracellular Matrix-Driven Matrix Metalloproteinase Production in Endothelial Cells: Implications for Angiogenesis [In Process Citation]. Trends. Cardiovasc. Med. 1999; 9: 70–77
   PubMed Web of Science ®Google Scholar
• O'Reilly M. S., Wiederschain D., Stetler-Stevenson W. G., Folkman J., Moses M. A. Regulation of Angiostatin Production by Matrix Metalloproteinase-2 in a Model of Concomitant Resistance. J. Biol. Chem. 1999; 274: 29568–29571
   PubMed Web of Science ®Google Scholar
• Kurizaki T., Toi M., Tominaga T. Relationship Between Matrix Metalloproteinase Expression and Tumor Angiogenesis in Human Breast Carcinoma. Oncol. Rep. 1998; 5: 673–677
   PubMed Web of Science ®Google Scholar
• Brooks P. C., Stromblad S., Sanders L. C., von Schalscha T. L., Aimes R. T., Stetler-Stevenson W. G., Quigley J. P., Cheresh D. A. Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction With Integrin Alpha v Beta 3. Cell 1996; 85: 683–693
   PubMed Web of Science ®Google Scholar
• Shalinsky D. R., Brekken J., Zou H., McDermott C. D., Forsyth P., Edwards D., Margosiak S., Bender S., Truitt G., Wood A., Varki N. M., Appelt K. Broad Antitumor and Antiangiogenic Activities of AG3340, A Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials. Ann. N. Y. Acad. Sci. 1999; 878: 236–270
   PubMed Web of Science ®Google Scholar
• Wilson M. J., Sinha A. A. Human Prostate Tumor Angiogenesis in Nude Mice: Metalloprotease and Plasminogen Activator Activities During Tumor Growth and Neovascularization of Subcutaneously Injected Matrigel Impregnated with Human Prostate Tumor Cells. Anat. Rec. 1997; 249: 63–73
   PubMedGoogle Scholar
• Achbarou A., Kaiser S., Tremblay G., Ste-Marie L. G., Brodt P., Goltzman D., Rabbani S. A. Urokinase Overproduction Results in Increased Skeletal Metastasis by Prostate Cancer Cells in Vivo. Cancer Res. 1994; 54: 2372–2377
   PubMed Web of Science ®Google Scholar
• Gaylis F. D., Keer H. N., Wilson M. J., Kwaan H. C., Sinha A. A., Kozlowski J. M. Plasminogen Activators in Human Prostate Cancer Cell Lines and Tumors: Correlation with the Aggressive Phenotype. J. Urol. 1989; 142: 193–198
   PubMed Web of Science ®Google Scholar
• Jimi S., Ito K., Kohno K., Ono M., Kuwano M., Itagaki Y., Ishikawa H. Modulation by Bovine Angiogenin of Tubular Morphogenesis and Expression of Plasminogen Activator in Bovine Endothelial Cells. Biochem. Biophys. Res. Commun. 1995; 211: 476–483
   PubMed Web of Science ®Google Scholar
• Peverali F. A., Mandriota S. J., Ciana P., Marelli R., Quax P., Rifkin D. B., Della Valle G., Mignatti P. Tumor Cells Secrete an Angiogenic Factor that Stimulates Basic Fibroblast Growth Factor and Urokinase Expression in Vascular Endothelial Cells. J. Cell. Physiol. 1994; 161: 1–14
   PubMed Web of Science ®Google Scholar
• Kumar R., Yoneda J., Bucana C. D., Fidler I. J. Regulation of Distinct Steps of Angiogenesis by Different Angiogenic Molecules. Int. J. Oncol. 1998; 12: 749–757
   PubMed Web of Science ®Google Scholar
• Cohen R. L., Xi X. P., Crowley C. W., Lucas B. K., Levinson A. D., Shuman M. A. Effects of Urokinase Receptor Occupancy on Plasmin Generation and Proteolysis of Basement Membrane by Human Tumor Cells. Blood 1991; 78: 479–487
   PubMed Web of Science ®Google Scholar
• Sage E. H., Vernon R. B. Regulation of Angiogenesis by Extracellular Matrix: The Growth and the Glue. J. Hypertens. Suppl. 1994; 12: S145–S152
   PubMedGoogle Scholar
• Ribatti D., Leali D., Vacca A., Giuliani R., Gualandris A., Roncali L., Nolli M. L., Presta M. In Vivo Angiogenic Activity of Urokinase: Role of Endogenous Fibroblast Growth Factor-2. J. Cell. Sci. 1999; 112: 4213–4221
   PubMed Web of Science ®Google Scholar
• Soff G. A., Sanderowitz J., Gately S., Verrusio E., Weiss I., Brem S., Kwaan H. C. Expression of Plasminogen Activator Inhibitor Type 1 by Human Prostate Carcinoma Cells Inhibits Primary Tumor Growth, Tumor-Associated Angiogenesis, and Metastasis to Lung and Liver in an Athymic Mouse Model. J. Clin. Invest. 1995; 96: 2593–2600
   PubMed Web of Science ®Google Scholar
• Ossowski L., Russo-Payne H., Wilson E. L. Inhibition of Urokinase-type Plasminogen Activator by Antibodies: The Effect on Dissemination of a Human Tumor in the Nude Mouse. Cancer Res. 1991; 51: 274–281
   PubMed Web of Science ®Google Scholar
• Ossowski L., Reich E. Antibodies to Plasminogen Activator Inhibit Human Tumor Metastasis. Cell 1983; 35: 611–619
   PubMed Web of Science ®Google Scholar
• Kellen J. A., Mirakian A., Kolin A. Antimetastatic Effect of Amiloride in an Animal Tumour Model. Anticancer Res. 1988; 8: 1373–1376
   PubMed Web of Science ®Google Scholar
• Towle M. J., Lee A., Maduakor E. C., Schwartz C. E., Bridges A. J., Littlefield B. A. Inhibition of Urokinase by 4-Substituted Benzo[b]thiophene-2-Carboxamidines: An Important New Class of Selective Synthetic Urokinase Inhibitor. Cancer Res. 1993; 53: 2553–2559
   PubMed Web of Science ®Google Scholar
• Evans C. P., Elfman F., Parangi S., Conn M., Cunha G., Shuman M. A. Inhibition of Prostate Cancer Neovascularization and Growth by Urokinase-Plasminogen Activator Receptor Blockade. Cancer Res. 1997; 57: 3594–3599
   PubMed Web of Science ®Google Scholar
• Joseph I. B., Isaacs J. T. Macrophage Role in the Anti-Prostate Cancer Response to one Class of Antiangiogenic Agents [See Comments]. J. Natl. Cancer Inst. 1998; 90: 1648–1653
   PubMed Web of Science ®Google Scholar
• Joseph I. B., Vukanovic J., Isaacs J. T. Antiangiogenic Treatment with Linomide as Chemoprevention for Prostate, Seminal Vesicle, and Breast Carcinogenesis in Rodents. Cancer Res. 1996; 56: 3404–3408
   PubMed Web of Science ®Google Scholar
• Vukanovic J., Hartley-Asp B., Isaacs J. T. Inhibition of Tumor Angiogenesis and the Therapeutic Ability of Linomide Against Rat Prostatic Cancers. Prostate 1995; 26: 235–246
   PubMed Web of Science ®Google Scholar
• Vukanovic J., Isaacs J. T. Linomide Inhibits Angiogenesis, Growth, Metastasis, and Macrophage Infiltration Within Rat Prostatic Cancers. Cancer Res. 1995; 55: 1499–1504
   PubMed Web of Science ®Google Scholar
• Vukanovic J., Isaacs J. T. Human Prostatic Cancer Cells are Sensitive to Programmed (Apoptotic) Death Induced by the Antiangiogenic Agent Linomide. Cancer Res. 1995; 55: 3517–3520
   PubMed Web of Science ®Google Scholar
• Kyprianou N., Isaacs J. T. Activation of Programmed Cell Death in the Rat Ventral Prostate After Castration. Endocrinology 1988; 122: 552–562
   PubMed Web of Science ®Google Scholar
• Kyprianou N., English H. F., Isaacs J. T. Programmed Cell Death During Regression of PC-82 Human Prostate Cancer Following Androgen Ablation. Cancer Res. 1990; 50: 3748–3753
   PubMed Web of Science ®Google Scholar
• Isaacs J. T. The Biology of Hormone Refractory Prostate Cancer. Why Does it Develop? Urol. Clin. North. Am. 1999; 26: 263–273
   Web of Science ®Google Scholar
• O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. H., Folkman J. Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma. Cell 1994; 79: 315–328
   PubMed Web of Science ®Google Scholar
• Holmgren L., O'Reilly M. S., Folkman J. Dormancy of Micrometastases: Balanced Proliferation and Apoptosis in the Presence of Angiogenesis Suppression [See Comments]. Nat. Med. 1995; 1: 149–153
   PubMed Web of Science ®Google Scholar
• O'Reilly M. S., Holmgren L., Chen C., Folkman J. Angiostatin Induces and Sustains Dormancy of Human Primary Tumors in Mice. Nat. Med. 1996; 2: 689–692
   PubMed Web of Science ®Google Scholar
• Lannutti B. J., Gately S. T., Quevedo M. E., Soff G. A., Paller A. S. Human Angiostatin Inhibits Murine Hemangioendothelioma Tumor Growth in Vivo. Cancer Res. 1997; 57: 5277–5280
   PubMed Web of Science ®Google Scholar
• Gately S., Twardowski P., Stack M. S., Patrick M., Boggio L., Cundiff D. L., Schnaper H. W., Madison L., Volpert O., Bouck N., Enghild J., Kwaan H. C., Soff G. A. Human Prostate Carcinoma Cells Express Enzymatic Activity that Converts Human Plasminogen to the Angiogenesis Inhibitor, Angiostatin. Cancer Res. 1996; 56: 4887–4890
   PubMed Web of Science ®Google Scholar
• Cao Y., Chen A., An S. S.A., Ji R. W., Davidson D., Llinas M. Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth. J. Biol. Chem. 1997; 272: 22924–22928
   PubMed Web of Science ®Google Scholar
• Cao R., Wu H. L., Veitonmaki N., Linden P., Farnebo J., Shi G. Y., Cao Y. Suppression of Angiogenesis and Tumor Growth by the Inhibitor K1-5 Generated by Plasmin-Mediated Proteolysis. Proc. Natl. Acad. Sci. USA 1999; 96: 5728–5733
   PubMed Web of Science ®Google Scholar
• O'Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R., Folkman J. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth. Cell 1997; 88: 277–285
   PubMed Web of Science ®Google Scholar
• Black W. R., Agner R. C. Tumour Regression After Endostatin Therapy [Letter]. Nature 1998; 391: 450
   PubMed Web of Science ®Google Scholar
• Boehm T., Folkman J., Browder T., O'Reilly M. S. Antiangiogenic Therapy of Experimental Cancer does not Induce Acquired Drug Resistance [See Comments]. Nature 1997; 390: 404–407
   PubMed Web of Science ®Google Scholar
• Yamaguchi N., Anand-Apte B., Lee M., Sasaki T., Fukai N., Shapiro R., Que I., Lowik C., Timpl R., Olsen B. R. Endostatin Inhibits VEGF-induced Endothelial Cell Migration and Tumor Growth Independently of Zinc Binding. Embo. J. 1999; 18: 4414–4423
   PubMed Web of Science ®Google Scholar
• Dhanabal M., Ramchandran R., Waterman M. J., Lu H., Knebelmann B., Segal M., Sukhatme V. P. Endostatin Induces Endothelial Cell Apoptosis. J. Biol. Chem. 1999; 274: 11721–11726
   PubMed Web of Science ®Google Scholar
• Miki T., Nonomura N., Nozawa M., Harada Y., Nishimura K., Kojima Y., Takahara S., Okuyama A. Angiogenesis Inhibitor TNP-470 Inhibits Growth and Metastasis of a Hormone-Independent Rat Prostatic Carcinoma Cell Line. J. Urol. 1998; 160: 210–213
   PubMed Web of Science ®Google Scholar
• Yamaoka M., Yamamoto T., Ikeyama S., Sudo K., Fujita T. Angiogenesis Inhibitor TNP-470 (AGM-1470) Potently Inhibits the Tumor Growth of Hormone-Independent Human Breast and Prostate Carcinoma Cell Lines. Cancer Res. 1993; 53: 5233–5236
   PubMed Web of Science ®Google Scholar
• Sin N., Meng L., Wang M. Q., Wen J. J., Bornmann W. G., Crews C. M. The Anti-Angiogenic Agent Fumagillin Covalently Binds and Inhibits the Methionine Aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA 1997; 94: 6099–6103
   PubMed Web of Science ®Google Scholar
• Riegman P. H., Vlietstra R. J., Suurmeijer L., Cleutjens C. B., Trapman J. Characterization of the Human Kallikrein Locus. Genomics 1992; 14: 6–11
   PubMed Web of Science ®Google Scholar
• Fortier A. H., Nelson B. J., Grella D. K., Holaday J. W. Antiangiogenic Activity of Prostate-Specific Antigen. J. Natl. Cancer Inst. 1999; 91: 1635–1640
   PubMed Web of Science ®Google Scholar
• Kim J. J., Trivedi N. N., Wilson D. M., Mahalingam S., Morrison L., Tsai A., Chattergoon M. A., Dang K., Patel M., Ahn L., Boyer J. D., Chalian A. A., Schoemaker H., Kieber-Emmons T., Agadjanyan M. A., Weiner D. B., Shoemaker H. Molecular and Immunological Analysis of Genetic Prostate Specific Antigen (PSA) Vaccine [Published Erratum Appears in Oncogene 1999, Apr., 8 18(14), 2411]. Oncogene 1998; 17: 3125–3135
   PubMed Web of Science ®Google Scholar
• Hodge J. W., Schlom J., Donohue S. J., Tomaszewski J. E., Wheeler C. W., Levine B. S., Gritz L., Panicali D., Kantor J. A. A Recombinant Vaccinia Virus Expressing Human Prostate-Specific Antigen (PSA): Safety and Immunogenicity in a Non-Human Primate. Int. J. Cancer 1995; 63: 231–237
   PubMed Web of Science ®Google Scholar